MRTX - FDA panel finds results from key Amgen Lumakras study unreliable
2023-10-05 15:13:58 ET
More on Amgen
- Amgen Inc. (AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)
- Amgen Inc. (AMGN) Citi Global Healthcare Conference (Transcript)
- Amgen: Not An Investment Mistake, But It Was Better Before
- Amgen wins Irish approval for planned Horizon Therapeutics purchase
- Amgen stock dips after FDA reveals concerns about Lumakras study (update)
For further details see:
FDA panel finds results from key Amgen Lumakras study unreliable